1 Final Shot for Hyped Alzheimer's Drug

Alzheimer's disease has been incredibly frustrating for the pharmaceutical industry. Decades of R&D have left little to show for the time and money spent. Designing successful treatments for a $600 billion worldwide problem (including dementia) is difficult when scientists don't totally understand what causes it. Eli Lilly is hoping to change that after announcing details around a new phase 3 trial for solanezumab.

In this video, health-care analyst David Williamson discusses Eli Lilly's struggle to combat Alzheimer's, how investors should react to today's news, and where it leaves Eli Lilly's stock going forward.

Still in the dark about how Obamacare might affect you and your portfolio? Don't worry -- you're not alone. To help prepare investors for the massive changes coming to the American health care system, The Motley Fool created a special free report that makes this complex topic easily understandable. Download "Everything You Need to Know About Obamacare" and discover how the law may affect your taxes, health insurance, and investments. Click here for your free copy today.

The article 1 Final Shot for Hyped Alzheimer's Drug originally appeared on Fool.com.

David Williamson owns shares of Johnson & Johnson and Eli Lilly. Follow David on Twitter: @MotleyDavid.The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.